{"schema_version":"1","generated_at":"2026-11-12T15:59:37.143Z","data_as_of":null,"url":"https://www.findmykol.com/kol/stanley-waintraub","json_url":"https://www.findmykol.com/kol/stanley-waintraub/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"stanley-waintraub","name":"Stanley Waintraub","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Hackensack University Medical Center","institution_url":"https://www.findmykol.com/institution/hackensack-university-medical-center","city":"Hackensack","state":"NJ","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1609835586","openalex":"A5069895705"},"summary":"Stanley Waintraub is an Oncology physician affiliated with Hackensack University Medical Center. OpenAlex indexes 31 publications with 408 citations (h-index 7).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":31,"cited_by_count":408,"h_index":7,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":11,"program_years":{"first":2021,"last":null},"rows_total":30,"shown":3,"withheld":27,"rows":[{"payer":"Gilead Sciences, Inc.","program_year":2025,"amount_usd":159.05,"payment_count":9,"source_url":"https://openpaymentsdata.cms.gov/search?query=1609835586"},{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":91.18,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1609835586"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":25.26,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1609835586"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1609835586","source":"payments"},"prescribing":{"data_year":2023,"areas_total":5,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":85.8,"classes_total":4,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":73.1,"drugs":[{"name":"Anastrozole","share_pct":62.3},{"name":"Exemestane","share_pct":22.8},{"name":"Letrozole","share_pct":13.3},{"name":"Arimidex","share_pct":1.6}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":10.9,"drugs":[{"name":"Ibrance","share_pct":61.7},{"name":"Verzenio","share_pct":29.1},{"name":"Erlotinib Hcl","share_pct":9.2}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":5.6,"classes_total":4,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":2.1,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":20},{"class":"Benzodiazepine","setting":"prescribed","share_pct":1.6,"drugs":[{"name":"Alprazolam","share_pct":100}],"max_beneficiaries":13}]},{"area":"Metabolism & gastrointestinal","share_pct":4.2,"classes_total":2,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":3,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":23},{"class":"Potassium supplement","setting":"prescribed","share_pct":1.2,"drugs":[{"name":"Potassium Chloride","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":96.3,"facility_pct":3.7},"source":"medicare"},"publications":{"total":31,"shown":5,"withheld":26,"matched_by":"OpenAlex author record","recent":[{"title":"Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1035","status":"verified"},{"title":"Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.3048","status":"verified"},{"title":"Multiple alternative splicing of HER2 transcripts and exon skipping with potential consequences on function and antibody-based therapy.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.1033","status":"verified"},{"title":"Defining low-HER2 cancers using RNA quantification by next generation sequencing.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.e13044","status":"verified"},{"title":"Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors","year":2023,"journal":"Heliyon","source_url":"https://doi.org/10.1016/j.heliyon.2023.e16261","status":"verified"}],"source":"works"},"similar":[{"name":"Michael Stifelman","slug":"michael-stifelman","institution":"Hackensack University Medical Center","specialty":"Urology","url":"https://www.findmykol.com/kol/michael-stifelman","json_url":"https://www.findmykol.com/kol/michael-stifelman/profile.json"},{"name":"Steven Ghanny","slug":"steven-ghanny","institution":"Hackensack University Medical Center","specialty":"Pediatric Endocrinology","url":"https://www.findmykol.com/kol/steven-ghanny","json_url":"https://www.findmykol.com/kol/steven-ghanny/profile.json"},{"name":"Andre Goy","slug":"andre-goy","institution":"Hackensack University Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/andre-goy","json_url":"https://www.findmykol.com/kol/andre-goy/profile.json"},{"name":"David Vesole","slug":"david-vesole","institution":"Hackensack University Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/david-vesole","json_url":"https://www.findmykol.com/kol/david-vesole/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":27,"publications":26}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}